• Joy

  Participated · Series A · Nov 2025

  Joy is a San Francisco-based company developing an advanced artificial-intelligence platform tailored to the needs of parents. Through its flagship offering, the Joy Parenting Club, members receive round-the-clock access to certified parenting professionals, including parent coaches and lactation consultants. The platform aims to improve every stage of the parenting journey by combining expert human guidance with AI-driven personalization. Looking ahead, Joy plans to deepen integrations with leading baby and parenting brands to create a more seamless ecosystem for families. The company also intends to expand its network of specialists so it can cover a wider range of childhood topics and developmental milestones. Newly secured capital will further accelerate product development, broaden service coverage, and enhance the underlying AI technology that powers user experiences.

• The Renatural

  Participated · Seed · Oct 2025

  The Renatural is a beauty-tech company revolutionizing the wig industry through robotics and proprietary materials. Its core products include The Wig Fix, a patented silicone band that secures wigs without glue, clips, or tape, and the newly launched Signature Wig Collection, a lace-free line of scalp-replica wigs produced in 45 minutes versus the industry norm of eight weeks. The company operates a proprietary machine roughly the size of a washing machine that individually injects hairs into an ultra-thin base, creating an undetectable finish and allowing free parting. Within three years of introducing The Wig Fix, The Renatural generated nearly $3 million in revenue and sold over 80,000 units worldwide. The Signature Collection offers textures such as Gentle Wave, Deep Curl, and Kinky Straight, priced between $950 and $1,950. Recent seed funding is earmarked for scaling production capacity and expanding the premium wig line. The brand has also earned accolades including the Glossier Alumni Award and backing from Harvard Business School and Yale University.

• WellTheory

  Participated · Series A · Oct 2025

  WellTheory offers a research-backed, virtual care program that addresses the root causes of autoimmune conditions through diet, lifestyle, and high-touch support from registered dietitians and certified health coaches. Its AI-powered platform, featuring proprietary tools Care Hub and Care Scribe, personalizes care plans and supports scalable delivery. In just 18 months on the market, the company has secured partnerships with Fortune 100 and 500 employers, high-growth companies such as Maven Clinic, Fortune Brands Innovations, and Dayforce, as well as payors like Sentara Health Plans and a top national payor. Independent claims analyses show the service reduces ER visits, imaging, hospitalizations, and biologics use, saving partners thousands of dollars per patient annually. Over the last year, WellTheory recorded 10× year-over-year member growth and 5× revenue growth, highlighting strong demand and business traction. With the latest financing, the company has raised $26.2 million in total and plans to deepen employer and payor partnerships, expand programs targeting high-cost autoimmune conditions, and further invest in its AI personalization capabilities.

• Gameto

  Participated · Series C · Aug 2025

  Gameto develops stem cell-derived therapies for reproductive health, with its lead program Fertilo using iPSC-derived engineered ovarian support cells to mature eggs outside the body. Fertilo is cleared for commercialization in multiple ex-U.S. jurisdictions (Peru, Mexico, Australia, Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay) and has been used in clinics with five babies born and over 20 pregnancies recorded. The therapy shortens standard ovarian stimulation from about two weeks of daily hormone injections to 2–3 days and is the first iPSC-derived therapy to reach late-stage clinical development in the U.S. Gameto is conducting a randomized, controlled, double-blind Phase 3 trial (FIRST) at up to 20 U.S. sites with an anticipated interim readout in late 2026. Beyond Fertilo, the company is developing the ARPA-H-funded Ameno menopause program, which includes an implantable cell therapy and a next-generation vaginal ring planned for Phase 1. Gameto's platform is built on an AI-powered in vitro organoid system developed with George Church's lab, and the company has raised $127 million to date. Gameto develops Fertilo, a novel investigational in vitro maturation (IVM) solution that uses engineered ovarian support cells (OSCs) to mature eggs outside the body. The company aims to make IVF and egg freezing shorter, safer, and more accessible by reducing hormonal injections. Gameto is led by CEO Dr. Dina Radenkovic and is already using Fertilo in clinical settings in Australia and Latin America. Following discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials subject to completion of certain assay and manufacturing requirements. The recent financing will support clinical development of Fertilo and continued commercial launches in markets where it is in use. Financially, the company reported a $33M Series B that brought total funding to $73M. Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Its underlying cell‑engineering platform was developed in stealth under a scientific research agreement with George Church’s lab at Harvard Medical School. The company is led by Dr. Dina Radenkovic and operates out of New York City and Madrid. In January it announced three sequenced programs: Fertilo (a biologic for IVF and egg freezing), Deovo (an organoid of the female reproductive system), and Ameno (a cell‑based therapeutic for primary ovarian insufficiency and menopause). Fertilo has entered preclinical development in partnership with clinics in the US and Spain, and partner clinics named include Extend Fertility, RMA, Pozitivf, Ovation Fertility, Clinica Tambre, and Hospital Ruber Internacional. Gameto intends to use the new funding to expand operations and broaden its business reach. Gameto is developing a platform for ovarian therapeutics that targets accelerated ovarian aging to change the trajectory of women’s health and equality. Its initial focus is on addressing menopause and improving assisted fertility through three sequenced programs: Fertilo, Deovo and Ameno. Fertilo aims to improve assisted fertility with a long-term mission to eliminate infertility; Deovo is initiating drug discovery and a computational platform for ovarian aging; Ameno aims to make the medical burden of menopause optional. The company is led by CEO Dr. Dina Radenkovic with Martin Varsavsky as chairman and is based in New York City and Boston, Massachusetts. Financially, Gameto disclosed a $20M Series A and a prior $3M seed (March 2020), totaling $23M in disclosed funding.

• Venteur

  Participated · Series A · Apr 2025

  Venteur provides a personalized health technology platform that helps employers offer employees tailored health benefits and full control over their choices via Individual Coverage Health Reimbursement Arrangements (ICHRA). The platform serves a range of companies, from small teams to businesses with over 5,000 employees. Venteur reports having served 30,000 employees across 600 businesses. The company is led by Stacy and Tim Edgar and is based in San Francisco, CA. Venteur plans to use its new funding to accelerate product innovation, expand into new markets, and grow its team. The product emphasis is on giving employees high-quality, personalized options rather than one-size-fits-all employer plans. Venteur operates a health insurance platform and services that enable businesses to provide their employees with more choice and control over care. The company positions its product to prioritize employee well-being and financial success. Venteur combines platform capabilities with services to simplify employer-sponsored health benefits. The startup is based in Berkeley, California. It recently completed a seed financing, indicating early-stage funding activity. Venteur plans to use the new capital to expand operations and advance its product development efforts.

No current team members are available.